01149nas a2200373   4500000000100000000000100001000000100002008004100003653001100044653004500055653004400100653005700144653001900201653007200220653003800292653006300330653002700393653002900420653001100449653001700460653002200477653002100499653002300520100001500543700001600558700001600574700001400590700001500604245010800619250001500727300001200742490000700754020001400761       2022                            d10aHumans10aCalcium Channel Blockers/adverse effects10aAntihypertensive Agents/therapeutic use10aSodium Chloride Symporter Inhibitors/adverse effects10aCohort Studies10a*Pancreatic Neoplasms/chemically induced/epidemiology/complications10a*Dihydropyridines/therapeutic use10a*Hypertension/drug therapy/epidemiology/chemically induced10aantihypertensive drugs10acalcium channel blockers10aCancer10aCohort study10aPancreatic cancer10apropensity score10aThiazide diuretics1 aJ. Rouette1 aE. McDonald1 aT. Schuster1 aJ. Brophy1 aL. Azoulay00aDihydropyridine Calcium Channel Blockers and Risk of Pancreatic Cancer: A Population-Based Cohort Study  a2022/12/15  ae0267890 v11  a2047-9980